脯氨酰羟化酶抑制药对肾保护作用的研究现状  

Research status of kidney protection by proline hydroxylase inhibitors

作　　者：胡月华 苏苗 陈强[2] HU Yue-Hua;SU Miao;CHEN Qiang(First Clinical Medical College,Baotou Medical College of Inner Mongolia University of Science and Technology,Baotou 014010,Inner Mongolia Autonomous Region,China;Cardiology Department,The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology,Baotou 014010,Inner Mongolia Autonomous Region,China;Pharmacy Department,The First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology,Baotou 014010,Inner Mongolia Autonomous Region,China)

机构地区：[1]内蒙古科技大学包头医学院第一临床医学院,内蒙古自治区包头014010 [2]内蒙古科技大学包头医学院第一附属医院心内科,内蒙古自治区包头014010 [3]内蒙古科技大学包头医学院第一附属医院药剂科,内蒙古自治区包头014010

出　　处：《中国临床药理学杂志》2024年第2期289-293,共5页The Chinese Journal of Clinical Pharmacology

基　　金：内蒙古自治区高等学校科学研究基金资助项目(NJZY19190);包头医学院科学研究基金资助项目(BYJJ-ZRQM 202226)。

摘　　要：靶向调节低氧诱导因子(HIF)通路能为炎性贫血、缺氧性肾病、慢性肾病相关心血管疾病以及其他缺氧性疾病提供治疗依据。目前,首个作用于HIF通路的罗沙司他已用于肾性贫血的治疗,其他的脯氨酰羟化酶(PHD)抑制药也处在临床研究中。本文主要综述PHD抑制药对肾保护作用的各种途径及机制。Targeted regulation of hypoxia inducible factor(HIF)pathway can provide therapeutic basis for inflammatory anemia,hypoxic nephropathy,cardiovascular diseases related to chronic kidney disease and other hypoxic diseases.At present,the first drug to act on the HIF pathway,roxadustat,has been used for the treatment of renal anemia,and other prolyl hydroxylase(PHD)inhibitors are also in clinical research.This article mainly reviews the various pathways and mechanisms of the protective effect of PHD inhibitors on the kidneys.

关 键 词：脯氨酰羟化酶抑制药 低氧诱导因子 肾保护 作用机制 

分 类 号：R97[医药卫生—药品]